An open labelled multi-centric clinical trial of safety and efficacy of Feijoa freeze dried powder (FFDP) capsules in treated uncontrolled type 2 diabetic patients

Viridis BioPharma Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

阶段: 3 期
状态: 尚未招募
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Type 2 DM patients (with duration of diabetes > 6 months) and treated with oral hypoglycemic medicines. HbA1c between 7 %to 9% .
•2.Patients in the age group between 19 to 65 years, of either sex.
•3.Willing to give informed consent.

排除标准

•1.Type 1 DM patients.
•2.Type 2 diabetic patients on insulin
•3.Pregnant women with diabetes
•4.Lactating mothers with diabetes
•5.Patient with uncontrolled diabetes, FBG >250mg% or PPBS >400mg% and/or HbA1c > 9.0.
•6.Patient with uncontrolled dyslipidemia (fasting S. cholesterol >260mg% and S. triglycerides > 300mg% on screening visit)
•7.Patient with presence of any severe diabetic complication and/or major systemic disease.
•8.S. Creatinine >1.5%.
•9.ASAT and ALT >2.5times the upper normal limits.
•10.Patients with recent stroke or unstable angina or coronary artery diseases in previous 6 months before inclusion.
•11.Presence of ketone bodies in urine analysis.
•12.Haemoglobin level below 10 gm%.
•13.History of substance abuse or alcoholism, within the previous one year.
•14.Patient with seropositive status.
•15.Patients who are on corticosteroids or oral contraceptives.
•16.Participation in clinical trials evaluating investigational pharmaceuticals or biologics within 3 months or devices within 30 days of admission to the study.
•17.Persons who have suffered from HIV/COVID, patients with Hepatitis C as per information given by patients

研究者

发起方

Viridis BioPharma Pvt Ltd

相似试验

招募中

不适用

Multicenter, open-label, non-controlled trial of short-term high dose dexamethasone therapy as initial treatment for idiopathic thrombocytopenic purpuraIdiopathic Thrombocytopenic Purpura

JPRN-UMIN000022415ATIONAL KYUSHU MEDICAL CENTER25

进行中（未招募）

1 期

EUCTR2016-004743-37-SEGenmab A/S25

进行中（未招募）

1 期

EUCTR2016-004743-37-GBGenmab A/S25

进行中（未招募）

1 期

A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factor

EUCTR2016-004743-37-HUGenmab A/S25

进行中（未招募）

1 期

A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factorCancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC

EUCTR2016-004743-37-BEGenmab A/S25